#molnupiravir — Public Fediverse posts

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

#SARS-CoV-2 Error Catastrophe Under #Molnupiravir: #Mutagenic Enhancement Enables Viral #Persistence with Impaired Fitness, https://etidiohnew.blogspot.com/2026/02/sars-cov-2-error-catastrophe-under.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

Effectiveness of #nirmatrelvir/ritonavir and #molnupiravir in reducing the #risk of short-term and long-term #cardiovascular complications of #COVID19: a target trial emulation study, https://etidiohnew.blogspot.com/2025/12/effectiveness-of-nirmatrelvirritonavir.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir clinical trial simulation suggests that #PCR underestimates #antiviral #potency against #SARS-CoV-2, https://etidiohnew.blogspot.com/2025/11/molnupiravir-clinical-trial-simulation.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Molnupiravir inhibits #Bourbon virus #infection and disease-associated #pathology in mice, https://etidiohnew.blogspot.com/2025/09/molnupiravir-inhibits-bourbon-virus.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

#Placental transfer of #medications to treat #COVID19, #molnupiravir, #favipiravir and #nirmatrelvir/ritonavir, in the ex vivo human cotyledon model, https://etidiohnew.blogspot.com/2025/09/placental-transfer-of-medications-to.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

The combinatorial activities of #oseltamivir and #molnupiravir against #influenza virus infections in vitro and in vivo, https://etidiohnew.blogspot.com/2025/07/the-combinatorial-activities-of.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

#Molnupiravir or #nirmatrelvir–ritonavir plus usual care vs usual care alone in patients admitted to #hospital with #COVID19 (RECOVERY)..., https://etidiohnew.blogspot.com/2025/05/molnupiravir-or-nirmatrelvirritonavir.html

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Health #outcomes 3 mos & 6 mos after #molnupiravir treatment for #COVID19 for people at higher #risk in #community (PANORAMIC): a RCT, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00431-6/fulltext?rss=yes

In a vaccinated population, people treated with molnupiravir for acute COVID19 felt better, experienced fewer & less severe symptoms, accessed health care less often, & took less time off work at 6 mos. However, absolute differences in this open-label design are small with high numbers needed to treat.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

Triple #combination of #Remdesivir, #Molnupiravir & #Ribavirin is highly efficient in inhibiting #coronavirus #replication in #human nasal #airway epithelial cell cultures & in a #hamster infection model. Antiviral Res.: https://www.sciencedirect.com/science/article/pii/S0166354224002031?via%3Dihub

Combining Remdesivir, molnupiravir, & ribavirin increases the antiviral efficacy against coronavirus OC43. This triple therapy also eliminates #SARS-CoV-2 replication in #lungs of infected hamsters, unlike double combinations.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

The triple #combination of #Remdesivir (GS-441524), #Molnupiravir and #Ribavirin is highly efficient in inhibiting #coronavirus #replication in human nasal #airway epithelial #cell cultures and in a hamster infection model http://biorxiv.org/cgi/content/short/2024.05.14.594200v1?rss=1

Our finding indicate that co-administration of approved drugs for treatment of CoVs infections should be further explored but also vs other families of viruses w/ epidemic and pandemic potential for which no effective antiviral treatment is available.

Randomized controlled #trial of #molnupiravir #SARS-CoV-2 viral and #antibody #response in at-#risk adult outpatients https://www.nature.com/articles/s41467-024-45641-0

-- In this clinical trial, the authors show that a 5-day molnupiravir treatment reduces SARS-CoV-2 viral load in at-risk outpatients by day 5 but mostly fails to clear virus, leads to lower spike antibody response by day 14 and higher virus mutation rates.

Randomized controlled #trial of #molnupiravir #SARS-CoV-2 viral and #antibody #response in at-#risk adult outpatients https://www.nature.com/articles/s41467-024-45641-0

-- In this clinical trial, the authors show that a 5-day molnupiravir treatment reduces SARS-CoV-2 viral load in at-risk outpatients by day 5 but mostly fails to clear virus, leads to lower spike antibody response by day 14 and higher virus mutation rates.

Randomized controlled #trial of #molnupiravir #SARS-CoV-2 viral and #antibody #response in at-#risk adult outpatients https://www.nature.com/articles/s41467-024-45641-0

-- In this clinical trial, the authors show that a 5-day molnupiravir treatment reduces SARS-CoV-2 viral load in at-risk outpatients by day 5 but mostly fails to clear virus, leads to lower spike antibody response by day 14 and higher virus mutation rates.

Randomized controlled #trial of #molnupiravir #SARS-CoV-2 viral and #antibody #response in at-#risk adult outpatients https://www.nature.com/articles/s41467-024-45641-0

-- In this clinical trial, the authors show that a 5-day molnupiravir treatment reduces SARS-CoV-2 viral load in at-risk outpatients by day 5 but mostly fails to clear virus, leads to lower spike antibody response by day 14 and higher virus mutation rates.

#Coronaausbruch bei #Katzen: >>Auf #Zypern starben Analysen zufolge seit Jahresbeginn Tausende Katzen an einem aggressiver gewordenen Tier-Coronavirus. Auch Großbritannien meldete im Oktober einen ersten eingeschleppten Fall - droht auch in Deutschland eine Ausbreitung des veränderten Erregers bei Katzen? "Aktuell sind noch keine Krankheitsausbrüche in Deutschland beschrieben, die den Verdacht auf diese neue Virusvariante zulassen", sagt Katrin Hartmann von der Kleintierklinik der Ludwig-Maximilians-Universität (LMU) München. Das Risiko sei durch den #Import infizierter Katzen aber gegeben. "Die aktuellen Fälle in #England werden auf den Import von Katzen aus Zypern zurückgeführt." Auf Zypern gibt es eine große Population herrenloser Katzen, die ähnlich wie südeuropäische #Straßenhunde häufig in andere Teile Europas und in die ganze Welt gebracht werden.
Die feline infektiöse #Peritonitis (#FIP) ist eine Krankheit von #Katzen, wie Hartmann erläutert. Es handle sich um eine schon lange weltweit bekannte Erkrankung, ausgelöst vom felinen Coronavirus (#FCoV). Auch in Deutschland komme dieser Erreger vor, der aber meist keine Symptome oder höchstens milden Durchfall verursache. Selten komme es zu einer spontanen Veränderung des harmlosen Virus, und die Katze erkranke an FIP. Auf erste unspezifische Symptome wie Appetitlosigkeit und Fieber folgen der Fachtierärztin zufolge dann Flüssigkeitsansammlungen etwa in Bauch- und Brusthöhle sowie teils auch neurologische Symptome und Augenprobleme. In Zypern und Großbritannien wurde nun aber ein neues felines Coronavirus nachgewiesen, #FCoV-23. Es handle sich um eine Mischung aus dem ursprünglichen FCoV und dem Hunde-Coronavirus CCoV [..] Auf Zypern wurde im August der Einsatz des Human-Coronavirus-Wirkstoffs #Molnupiravir zur Behandlung von Katzen mit FIP genehmigt. Als sehr effektiv [...]<< https://www.sueddeutsche.de/wissen/coronavirus-katzen-zypern-1.6322915 #caturday #catsofmastodon #catodon

#Coronaausbruch bei #Katzen: >>Auf #Zypern starben Analysen zufolge seit Jahresbeginn Tausende Katzen an einem aggressiver gewordenen Tier-Coronavirus. Auch Großbritannien meldete im Oktober einen ersten eingeschleppten Fall - droht auch in Deutschland eine Ausbreitung des veränderten Erregers bei Katzen? "Aktuell sind noch keine Krankheitsausbrüche in Deutschland beschrieben, die den Verdacht auf diese neue Virusvariante zulassen", sagt Katrin Hartmann von der Kleintierklinik der Ludwig-Maximilians-Universität (LMU) München. Das Risiko sei durch den #Import infizierter Katzen aber gegeben. "Die aktuellen Fälle in #England werden auf den Import von Katzen aus Zypern zurückgeführt." Auf Zypern gibt es eine große Population herrenloser Katzen, die ähnlich wie südeuropäische #Straßenhunde häufig in andere Teile Europas und in die ganze Welt gebracht werden.
Die feline infektiöse #Peritonitis (#FIP) ist eine Krankheit von #Katzen, wie Hartmann erläutert. Es handle sich um eine schon lange weltweit bekannte Erkrankung, ausgelöst vom felinen Coronavirus (#FCoV). Auch in Deutschland komme dieser Erreger vor, der aber meist keine Symptome oder höchstens milden Durchfall verursache. Selten komme es zu einer spontanen Veränderung des harmlosen Virus, und die Katze erkranke an FIP. Auf erste unspezifische Symptome wie Appetitlosigkeit und Fieber folgen der Fachtierärztin zufolge dann Flüssigkeitsansammlungen etwa in Bauch- und Brusthöhle sowie teils auch neurologische Symptome und Augenprobleme. In Zypern und Großbritannien wurde nun aber ein neues felines Coronavirus nachgewiesen, #FCoV-23. Es handle sich um eine Mischung aus dem ursprünglichen FCoV und dem Hunde-Coronavirus CCoV [..] Auf Zypern wurde im August der Einsatz des Human-Coronavirus-Wirkstoffs #Molnupiravir zur Behandlung von Katzen mit FIP genehmigt. Als sehr effektiv [...]<< https://www.sueddeutsche.de/wissen/coronavirus-katzen-zypern-1.6322915 #caturday #catsofmastodon #catodon

#Coronaausbruch bei #Katzen: >>Auf #Zypern starben Analysen zufolge seit Jahresbeginn Tausende Katzen an einem aggressiver gewordenen Tier-Coronavirus. Auch Großbritannien meldete im Oktober einen ersten eingeschleppten Fall - droht auch in Deutschland eine Ausbreitung des veränderten Erregers bei Katzen? "Aktuell sind noch keine Krankheitsausbrüche in Deutschland beschrieben, die den Verdacht auf diese neue Virusvariante zulassen", sagt Katrin Hartmann von der Kleintierklinik der Ludwig-Maximilians-Universität (LMU) München. Das Risiko sei durch den #Import infizierter Katzen aber gegeben. "Die aktuellen Fälle in #England werden auf den Import von Katzen aus Zypern zurückgeführt." Auf Zypern gibt es eine große Population herrenloser Katzen, die ähnlich wie südeuropäische #Straßenhunde häufig in andere Teile Europas und in die ganze Welt gebracht werden.
Die feline infektiöse #Peritonitis (#FIP) ist eine Krankheit von #Katzen, wie Hartmann erläutert. Es handle sich um eine schon lange weltweit bekannte Erkrankung, ausgelöst vom felinen Coronavirus (#FCoV). Auch in Deutschland komme dieser Erreger vor, der aber meist keine Symptome oder höchstens milden Durchfall verursache. Selten komme es zu einer spontanen Veränderung des harmlosen Virus, und die Katze erkranke an FIP. Auf erste unspezifische Symptome wie Appetitlosigkeit und Fieber folgen der Fachtierärztin zufolge dann Flüssigkeitsansammlungen etwa in Bauch- und Brusthöhle sowie teils auch neurologische Symptome und Augenprobleme. In Zypern und Großbritannien wurde nun aber ein neues felines Coronavirus nachgewiesen, #FCoV-23. Es handle sich um eine Mischung aus dem ursprünglichen FCoV und dem Hunde-Coronavirus CCoV [..] Auf Zypern wurde im August der Einsatz des Human-Coronavirus-Wirkstoffs #Molnupiravir zur Behandlung von Katzen mit FIP genehmigt. Als sehr effektiv [...]<< https://www.sueddeutsche.de/wissen/coronavirus-katzen-zypern-1.6322915 #caturday #catsofmastodon #catodon

@lzvolk agreed completely. Sally Otto and I wrote about the theoretical possibility in Nov 2021 - https://virological.org/t/mutagenic-antivirals-the-evolutionary-risk-of-low-doses/768

... as did many others around the same time. #Merck had relevant #molnupiravir data (e.g. BAM or VCF files) but simply didn't make them available. Thus, it's taken awhile for sufficient data to be collected in the real world. Bravo to Sanderson et al. for doing so!

@lzvolk agreed completely. Sally Otto and I wrote about the theoretical possibility in Nov 2021 - https://virological.org/t/mutagenic-antivirals-the-evolutionary-risk-of-low-doses/768

... as did many others around the same time. #Merck had relevant #molnupiravir data (e.g. BAM or VCF files) but simply didn't make them available. Thus, it's taken awhile for sufficient data to be collected in the real world. Bravo to Sanderson et al. for doing so!

@lzvolk agreed completely. Sally Otto and I wrote about the theoretical possibility in Nov 2021 - https://virological.org/t/mutagenic-antivirals-the-evolutionary-risk-of-low-doses/768

... as did many others around the same time. #Merck had relevant #molnupiravir data (e.g. BAM or VCF files) but simply didn't make them available. Thus, it's taken awhile for sufficient data to be collected in the real world. Bravo to Sanderson et al. for doing so!

@lzvolk agreed completely. Sally Otto and I wrote about the theoretical possibility in Nov 2021 - https://virological.org/t/mutagenic-antivirals-the-evolutionary-risk-of-low-doses/768

... as did many others around the same time. #Merck had relevant #molnupiravir data (e.g. BAM or VCF files) but simply didn't make them available. Thus, it's taken awhile for sufficient data to be collected in the real world. Bravo to Sanderson et al. for doing so!

Some interpret concerns about #molnupiravir to be that it imposes selection, just like other drugs.

The real issue is that it’s a mutagen: it increases the initial rate of viral mutations, even before selection takes place. Thus it may speed the generation of new mutation combos. https://www.nature.com/articles/d41586-023-03248-3

Some interpret concerns about #molnupiravir to be that it imposes selection, just like other drugs.

The real issue is that it’s a mutagen: it increases the initial rate of viral mutations, even before selection takes place. Thus it may speed the generation of new mutation combos. https://www.nature.com/articles/d41586-023-03248-3

Some interpret concerns about #molnupiravir to be that it imposes selection, just like other drugs.

The real issue is that it’s a mutagen: it increases the initial rate of viral mutations, even before selection takes place. Thus it may speed the generation of new mutation combos. https://www.nature.com/articles/d41586-023-03248-3